Obestatin
Also known as: preproghrelin-derived peptide, ghrelin gene-derived peptide, GHRL gene product
Endogenous gut peptide hormone; 23-amino-acid peptide derived from post-translational cleavage of the preproghrelin precursor protein
What it is
Obestatin is a gut-derived peptide hormone studied by researchers interested in appetite control, muscle health, and metabolic diseases. It comes from the same gene as ghrelin and is explored for its potential to counteract muscle wasting, support wound healing, and act as a biomarker in conditions like obesity and inflammatory bowel disease.
The scientific side
obestatin is a 23-amino-acid peptide produced by post-translational processing of the preproghrelin precursor, encoded by the GHRL gene. It is co-secreted with ghrelin from gastric and intestinal cells and circulates in blood, where it is rapidly degraded by proteases in the blood, liver, and kidneys. Obestatin has historically been proposed to act through GPR39, a G protein-coupled receptor related to the ghrelin/neurotensin receptor subfamily expressed in the pancreas, gastrointestinal tract, liver, kidney, and brain, although subsequent in vitro studies have challenged whether obestatin directly binds GPR39. Zinc ions (Zn2+) are now recognised as potent endogenous agonists of GPR39 via the Galphaq, Galphas, and Galpha12/13 pathways. In skeletal muscle, the obestatin/GPR39 system operates as an autocrine anabolic signalling axis: it integrates 5' AMP-activated protein kinase (AMPK) and mTORC1 pathways to control the ubiquitin-proteasome system, the autophagy-lysosome system, and protein synthesis. In Duchenne muscular dystrophy (DMD) models, obestatin reactivates autophagy through NEDD4-L-mediated deubiquitination and ULK1/VPS34 complex assembly, and separately restores mitochondrial biogenesis and membrane repair through the calcineurin (PPP3) and transcription factors TFEB and NFATc1. Obestatin promotes vascularisation and reduces fibrosis in acutely injured muscle while increasing Pax7-driven muscle stem cell mobilisation. In the hypothalamus, obestatin interacts with neuropeptide Y and agouti-related peptide pathways, modulating the somatotrophic and gonadotrophic axes in a species-dependent manner. In the gut and metabolic axis, obestatin is typically reduced in obesity and type 2 diabetes, and its circulating levels increase modestly with GLP-1 receptor agonist treatment. The obestatin/ghrelin ratio has been proposed as a biomarker of active inflammatory bowel disease activity. In wound-healing models, obestatin incorporated into alginate/chitosan hydrogels upregulates VEGF, collagen type I and III, and TGF-beta mRNA expression.
Class: Endogenous gut peptide hormone; 23-amino-acid peptide derived from post-translational cleavage of the preproghrelin precursor protein
Administration & storage
- Administration
- Intraperitoneal injection (animal models)Topical hydrogel delivery incorporated into alginate/chitosan scaffold (wound model)
- Storage
- Synthetic obestatin peptide is typically stored lyophilised at -20°C or below and protected from light and moisture; no human pharmaceutical formulation storage data exist
Legal & regulatory status
Not approved for any therapeutic indication; no FDA-cleared drug product containing obestatin exists
Not listed as a prohibited substance in publicly available WADA documentation reviewed at the time of this record
Not approved for any therapeutic indication
What it's studied for
- Skeletal muscle atrophy and Duchenne muscular dystrophy (preclinical) Preclinical only (human cell lines + rodent/mdx models)
- Appetite suppression and obesity-related metabolic parameters (animal models) Preclinical only (rodent models)
- Biomarker of disease activity in inflammatory bowel disease Clinical observational (systematic review and meta-analysis of human studies)
- Skin wound healing (preclinical hydrogel delivery model) Preclinical only (rat full-thickness wound model)
- Biomarker of glycaemic response to GLP-1 receptor agonist therapy in type 2 diabetes Clinical observational (prospective cohort, n=67)
- Peripheral biomarker elevated in anorexia nervosa Clinical observational (meta-analysis of case-control studies)
- Neuroendocrine modulation: somatotrophic and gonadotrophic axes (animal models) Preclinical only (rodent and sheep models)
- Cardioprotection (narrative review; original research retracted) Narrative review only; note: one key original study retracted
Safety signals
- Haemolysis at high concentrations in hydrogel wound model
- Retraction of cardiac ischaemia-reperfusion original research
- Rapid proteolytic degradation in vivo limits bioavailability
- Reduced insulin and adiponectin levels in obestatin-treated obese mice
- Inconsistent and species-dependent effects on food intake and body weight
- Obestatin receptor (GPR39) binding remains disputed
- Elevated obestatin levels in anorexia nervosa associated with starvation adaptation
No peer-reviewed studies indexed for this peptide yet.
Frequently asked
What is obestatin and where does it come from?
Obestatin is a 23-amino-acid peptide hormone produced in the stomach and intestine by post-translational cleavage of the preproghrelin precursor protein, which is encoded by the GHRL gene — the same gene that produces ghrelin. It circulates in the bloodstream but is rapidly broken down by proteases in the blood, liver, and kidneys.
Does obestatin suppress appetite or help with weight loss?
In animal models, obestatin has been studied for its potential to modulate appetite-related hormones and reduce body weight in diet-induced obese mice, and some fish models suggest it can partially block ghrelin-stimulated food intake. However, these are preclinical findings. There are no approved human treatments using obestatin, and no clinical trials have tested it as a weight-loss therapy in humans.
Is obestatin being studied for muscle wasting or Duchenne muscular dystrophy?
Yes, preclinical research — primarily using human cell lines and mouse models of Duchenne muscular dystrophy — has investigated obestatin as a potential approach to counteract muscle wasting. Studies report that it activates autophagy and mitochondrial repair pathways in dystrophic muscle. No human clinical trials of obestatin for muscle disease have been identified in publicly available registries.
Can obestatin be used to improve wound healing?
One preclinical rat study tested obestatin delivered in a hydrogel scaffold and found improved wound closure and upregulation of wound-healing genes at 100 µM; however, higher concentrations caused increased haemolysis. This research is at an early stage and no human data exist.
Is obestatin safe for human use?
Obestatin has not been approved or rigorously tested as a drug in humans. A key original study reporting cardioprotective effects of obestatin was retracted in 2023 due to data integrity concerns. Preclinical studies suggest dose-dependent adverse effects (haemolysis at high concentrations), rapid degradation in circulation, and inconsistent biological responses across species. Safety data in humans are not available.
What is the obestatin/ghrelin ratio used for clinically?
Research in inflammatory bowel disease patients has found that the obestatin/ghrelin ratio is significantly lower in active IBD compared with remission, and has been proposed as a potential disease-activity biomarker. It is not in routine clinical use and further validation studies are needed.